NCT00622388View on ClinicalTrials.gov

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

81

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

August 31, 2014

Conditions

Lymphoma, Large-Cell, Diffuse

Interventions

DRUG

Ofatumumab

8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg

Trial Locations (1)

EC1M 6BQ

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY